Angiotensin II receptor blockers and oral squamous cell carcinoma survival: A propensity-score-matched cohort study.

Ching-Nung WuShao-Chun WuWei-Chih ChenYao-Hsu YangJo-Chi ChinChih-Yen ChienFu-Min FangShau-Hsuan LiSheng-Dean Luo Tai-Jan Chiu

Published in: PloS one (2021)

ARB use for more than 180 days is associated with an increased survival rate and is a positive, independent prognostic factor in patients with OSCC. A further two-arm study should be conducted to confirm the clinical usefulness of ARBs in OSCC patients.

Keyphrases

prognostic factors
angiotensin ii
angiotensin converting enzyme
end stage renal disease
vascular smooth muscle cells
ejection fraction
free survival
peritoneal dialysis
patient reported
binding protein